Abbott Laboratories (ABT) stock analysis
Company overview and business model
Source fact: Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Classification: NYSE · Healthcare · Medical Devices
Revenue and growth
Source fact: Revenue was USD 44.33 billion for the period ending 2025-12-31.
Caverian calculation: Revenue changed +5.7% (FY2025 vs FY2024).
Profitability
Source fact: Net income was USD 6.52 billion in the latest reported period.
Source metric: Reported net margin was 14.7%.
Balance sheet and liquidity
Source fact: Cash and equivalents were USD 8.52 billion.
Source fact: Total debt was USD 13.86 billion.
Source metric: Current ratio was 1.58x.
Cash-flow analysis
Source fact: Operating cash flow was USD 9.57 billion.
Source fact: Free cash flow was USD 7.39 billion.
Valuation
Source metrics: Trailing P/E 37.01x; Forward P/E 18.86x; Price to book 3.87x; Price to sales 4.25x; EV/EBITDA 19.33x.
Caverian model output: Value score was 40/100.
Competitive position
Classification: Peer context: Medical Devices within Healthcare.
Caverian model output: Quality score was 71/100.
Caverian model output: Growth score was 49/100.
Material risks
Caverian calculation: Altman Z-score was 5.29 (safe zone).
Caverian calculation: Piotroski F-score was 5/9.
Data sources and freshness
Freshness: This report uses a stored upstream snapshot; statement periods are shown alongside the figures.
Methodology and limitations
Facts reproduce stored upstream fields. Calculations derive only from the displayed stored statements. Model outputs are Caverian interpretations, not investment advice or a buy/sell recommendation.
How Caverian approaches valuation · Sources and product principles